EBS - Emergent Biosolutions Non-GAAP EPS of -$1.27 misses by $1.14 revenue of $240M misses by $26.35M; cuts FY22 outlook
- Emergent Biosolutions press release ( NYSE: EBS ): Q3 Non-GAAP EPS of -$1.27 misses by $1.14 .
- Revenue of $240M (-27.1% Y/Y) misses by $26.35M .
- Guidance 2022:
- Total Revenues $1.05B to $1.1B. Prior total revenue outlook of $1.15B to $1.25B vs. consensus of $1.19B.
- Adjusted Net Income -$100M to -$70M; Prior Adjusted net income outlook of -$15M to $10M.
For further details see:
Emergent Biosolutions Non-GAAP EPS of -$1.27 misses by $1.14, revenue of $240M misses by $26.35M; cuts FY22 outlook